Sinco Pharmaceuticals Holdings Limited 2025 Annual Results: Key Takeaways for Investors

Executive Summary

Sinco Pharmaceuticals Holdings Limited (“Sinco” or “the Group”) has released its audited annual results for the year ended 31 December 2025, revealing a period of significant operational challenges and strategic recalibration. The company faced headwinds with declining revenues and profits, but maintained a strong balance sheet and continued its focus on innovation and quality growth. Several elements in this report are especially relevant and potentially price-sensitive for shareholders.

Key Financial Highlights

• Revenue Decline: Total revenue decreased by 26.1% to RMB2,084.6 million (2024: RMB2,821.3 million). This drop was primarily driven by a sharp reduction in sales volume of human albumin solution, resulting in a revenue decrease of approximately RMB720 million in this segment.
• Gross Profit and Margin: Gross profit fell by RMB77.8 million to RMB222.1 million (2024: RMB299.9 million). The gross profit margin remained stable at 10.7% (2024: 10.6%), indicating the fall in profitability was in line with lower sales rather than margin erosion.
• Net Profit: Net profit attributable to owners was RMB34.9 million, down 16.9% from RMB42.0 million. The decrease was influenced by lower revenues but was partially offset by reduced operating costs.
• Earnings Per Share: Basic and diluted EPS stood at RMB0.017 (2024: RMB0.02).
• Dividend: The board has proposed a final dividend of HK0.167 cents per ordinary share (2024: HK0.20 cents), totaling HK\$3,400,000, subject to shareholder approval. The dividend cut reflects the company’s conservative approach amid uncertainties.

Operational and Strategic Developments

• Market Challenges: The Group operated in an environment of easing global macroeconomic recovery, persistent uncertainties, and heightened competition in the domestic pharmaceutical industry, especially in blood products.
• Cost Controls: Management reduced selling and distribution expenses by RMB6.3 million, mainly through lower marketing expenses, and administrative expenses by RMB43.3 million, thanks to reduced R&D, staff, intermediary, and tax costs.
• Cash Flow and Gearing: The company generated strong net cash from operations (RMB222.7 million) and reduced borrowings from RMB340.9 million to RMB179.7 million. The gearing ratio improved to 52.2% from 57.5%, reflecting prudent balance sheet management.
• Capital Expenditure: Capex was reduced to RMB10 million from RMB35.2 million, emphasizing discipline in resource allocation.

Risk Factors and Key Shareholder Considerations

• Supplier Concentration: The largest supplier accounted for 99.88% of purchases. The concentration risk is significant, as any disruption may impact business continuity.
• Customer Concentration: The top five customers comprised 64.58% of revenue. Loss of a major customer could materially impact results.
• Foreign Exchange Risk: The Group has exposure to USD, HKD, and SGD. A 5% change in exchange rates could impact profit before tax by several hundred thousand RMB. Macroeconomic and FX volatility could affect future earnings.
• Regulatory Compliance: The Group confirmed full compliance with applicable laws in the Cayman Islands, BVI, Hong Kong, and PRC.

Corporate Actions and Shareholder Matters

• Dividend Policy and AGM: The final dividend is subject to approval at the AGM on 15 May 2026. The register of members will be closed from 21 May to 26 May 2026 for dividend entitlement purposes. Payment is expected around 4 June 2026.
• Share Option Scheme: The 2025 Share Option Scheme was approved, with up to 10% of share capital reserved for issuance over the next decade. No options have yet been granted.
• Major Shareholders: Risun Investments Limited, controlled by Mr. Huang, holds 51.65% of shares, indicating stable control and alignment of interests but also a potential liquidity constraint for the free float.

Corporate Governance and Audit

• Governance: The Group continues to comply with the Hong Kong Corporate Governance Code, emphasizing risk management, internal controls, and effective board oversight.
• Audit: Rongcheng (Hong Kong) CPA Limited audited the financials and found no material issues. The auditor’s remuneration was approximately RMB2 million for audit services and RMB0.68 million for non-audit services.
• Whistleblowing and Anti-Corruption: The Group maintains updated whistleblowing and anti-corruption policies, with no material incidents reported during the year.

Other Notable Events

• Financing Activities: The Group had a net cash outflow in financing activities (RMB236.1 million), due mainly to significant repayments of borrowings and increased pledged deposits.
• Environmental and Social Responsibility: The Group’s business has minimal environmental impact. Initiatives are in place for energy conservation and compliance with environmental laws.
• Related Party Transactions: Mr. Huang provided guarantees for Group loans. These are exempt from reporting requirements but are disclosed for transparency.
• Significant Events After Year-End: No material events requiring disclosure have occurred since 31 December 2025.

Potential Price-Sensitive Issues and Shareholder Implications

• Significant Revenue and Profit Decline: The sharp decrease in key product sales and overall profits could weigh on market sentiment and share price until a visible recovery path emerges.
• Dividend Reduction: The lower proposed dividend signals a conservative approach, possibly reflecting management’s cautious outlook.
• Supplier and Customer Concentration: High reliance on a single supplier and a handful of customers introduces substantial risk, which may concern institutional investors.
• Improved Gearing & Cash Management: The reduction in borrowings and improved gearing may provide some reassurance about financial stability.
• Corporate Actions: The new share option scheme, if exercised, could dilute existing shareholders but is also a tool for employee retention.

Conclusion

Sinco Pharmaceuticals faces a challenging environment, with declining core product sales and profits. However, the Group has responded with cost controls, deleveraging, and continued investment in core businesses. The dividend cut and heightened supplier/customer concentration are key risks to monitor. The outcome of the AGM and shareholder approval for the final dividend will be closely watched.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult their financial advisors before making investment decisions. The information is derived from the 2025 Annual Report of Sinco Pharmaceuticals Holdings Limited and is believed to be accurate at the time of publication, but no warranty is given as to its accuracy or completeness. Market conditions and company prospects may change without notice.

View SINCO PHARMA Historical chart here